Skip to main content

Specialty Menu Navigation

  • COVID-19

  • Clinical

  • Coronary

  • Structural

  • Endovascular

  • Heart Failure

  • Heart Rhythm

  • Imaging & Physiology

  • Policy & Practice

Top User Menu

  • CME
  • Register
  • Login
Advertisement

Main navigation

  • News
    • Conference News
    • Features
    • Opinion
  • Conferences
  • Slides
  • Specialties
    • COVID-19
    • Clinical
    • Coronary
    • Structural
    • Endovascular
    • Heart Failure
    • Heart Rhythm
    • Imaging & Physiology
    • Policy & Practice
  • Podcasts
    • Heart Sounds
    • Rox Heart Radio
    • TCTMD Talking Points
    • Taking It To Heart
    • Heart Valve Matters
  • Videos
    • All Videos
    • Interviews
    • Topical Discussions
    • On Record
    • Live Cases
    • Partner Content
  • Fellows Forum
  • CV Team Forum
  • Slides (179)
  • News (61)
Podcast
  • Conference News
  • Editor's Corner
  • Daily News
  • Off Script
  • (-) TCT (240)
  • ACS/AMI (76)
  • Coronary (53)
  • DES/BRS/DCB (21)
  • Cath Lab (19)
  • Clinical Cardiology (18)
  • Clinical Pharma (16)
  • Policy & Practice (13)
  • Prevention (11)
  • Imaging & Physiology (9)
  • Lipids (9)
  • Angiography/QCA (6)
  • Cardiac Surgery (6)
  • Guidelines (4)
  • CTO (3)
  • Hemodynamic Support (3)
  • Structural Heart (3)
  • Diabetes (2)
  • Endovascular (2)
  • Heart Failure (2)
  • Heart Rhythm (2)
  • IVUS/NIRS (2)
  • Left Atrial Appendage (2)
  • OCT (2)
  • Plaque Modification (2)
  • Quality (2)
  • Training (2)
  • Vascular Access/Closure (2)
  • Women's Heart (2)
  • Aortic (1)
  • Aortic Valve (1)
  • Atrial Fibrillation (1)
  • Congenital (1)
  • CT/CT-FFR (1)
  • FFR (1)
  • Heart Rhythm Pharma (1)
  • Mitral Valve (1)
  • PFO/ASD (1)
  • Public Health (1)
  • Tricuspid Valve (1)
  • (-) CAD Pharma (240)
  • 2024 (1)
  • 2023 (3)
  • 2022 (3)
  • 2021 (10)
  • 2020 (9)
  • 2019 (10)
  • 2018 (7)
  • 2017 (3)
  • 2016 (192)
Displaying 161 - 180 of 240
Sort: Relevancy | Date
Impact of bivalirudin on peri-procedural events in patients undergoing rotational atherectomy: a subanalysis of the randomized ROTAXUS trial
Presentation TCT 2013

Impact of bivalirudin on peri-procedural events in patients undergoing rotational atherectomy: a subanalysis of the randomized ROTAXUS trial

Presenter: Mohamed Abdel-Wahab, Ahmed Khattab, Heinz Joachim B?ttner, Ralph Toelg, Volker Geist, Thomas Meinertz, Franz-Josef Neumann, Gert Richardt
January 31, 2013
Impact of Anti-anginal Therapy and Rate Pressure Product Control on the Need for Repeat Revascularization Post-PCI
Presentation TCT 2013

Impact of Anti-anginal Therapy and Rate Pressure Product Control on the Need for Repeat Revascularization Post-PCI

Presenter: Subhash Banerjee, Rick Weideman, Bertis Little, Mark Weideman, Jennifer Gunter, Kevin Kelly, Emmanouil Brilakis
January 31, 2013
Heparin Versus Bivalirudin– In-hospital And 30 Day MACE In Patients Having DES Implantation
Presentation TCT 2013

Heparin Versus Bivalirudin– In-hospital And 30 Day MACE In Patients Having DES Implantation

Presenter: Evan Shlofmitz, Richard Shlofmitz, Simcha Pollack, Elizabeth Cormier, Elizabeth Haag, Nathaniel Reichek
January 31, 2013
Effect of Ticagrelor on the Outcomes of Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From The PLATelet inhibition and patient Outcomes (PLATO) trial
Presentation TCT 2013

Effect of Ticagrelor on the Outcomes of Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From The PLATelet inhibition and patient Outcomes (PLATO) trial

Presenter: Emmanouil Brilakis, Claes Held, Bernhard Meier, Frank Cools, Marc Claeys, Jan Cornel, Philip Aylward, Basil Lewis, Douglas Weaver, Gunnar Brandrup- Wognsen, Susanna Stevens, Lars Wallentin, Stefan James
January 31, 2013
Ecarin Clotting Time (ECT) more accurately reflects bivalirudin concentration than Activated Clotting Time (ACT) in patients undergoing Percutaneous Coronary Intervention using...
Presentation TCT 2013

Ecarin Clotting Time (ECT) more accurately reflects bivalirudin concentration than Activated Clotting Time (ACT) in patients undergoing Percutaneous Coronary Intervention using...

Presenter: Ronan Margey, Helen Ridgway, Richard Rullman, Jeff Spencer, Ronan Margey, Iris McNulty, Aditya Mangla, Sotir Polena, Daniel Soffer, Ik-Kyung Jang
January 31, 2013
Double (360mg) Loading Dose Of Ticagrelor In Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Presentation TCT 2013

Double (360mg) Loading Dose Of Ticagrelor In Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Presenter: Dimitrios Alexopoulos, Ioanna Xanthopoulou, Vassilios Gkizas, George Kassimis, Konstantinos Theodoropoulos, Tsigkas Grigorios, Ioannis Chiladakis, Anastasia Damelou, George Hahalis, Periklis Davlouros
January 31, 2013
Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention
Presentation TCT 2013

Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention

Presenter: Amit Sachdeva, Sumati Bavisetty, Gerald Beckham, Albert Shen, Vicken Aharonian, Prakash Mansukhani, Gregg Stone, Martin Leon, Jeffrey Moses, Naing Moore, Ric Hyett, Richard Contreras, Somjot Brar
January 31, 2013
Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry
Presentation TCT 2013

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Presenter: Renato Valenti, Angela Migliorini, Guido Parodi, Ruben Vergara, Nazario Carrabba, Emilio Vincenzo Dovellini, David Antoniucci
January 31, 2013
Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.
Presentation TCT 2013

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Presenter: Salvatore Cassese, Robert Byrne, Tomohisa Tada, Lamin King, Adnan Kastrati
January 31, 2013
Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?
Presentation TCT 2013

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Presenter: Andreas Baumbach, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran, Gregg Stone
January 31, 2013
Can Amelioration of HDL-C Level by Pitavastatin Improve Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention?
Presentation TCT 2013

Can Amelioration of HDL-C Level by Pitavastatin Improve Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention?

Presenter: Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Amro Elnagar, Sung Il Im, Sun Won Kim, Jin Oh Na, Seong Woo Han, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, Myung Ho Jeong
January 31, 2013
News Conference News TCT 2012

Aspirin, Cilostazol Combination Best After Angioplasty for Critical Limb Ischemia

November 01, 2012
Part 2: Antiplatelet Agents
Presentation TCT 2012

Part 2: Antiplatelet Agents

Presenter: Robert Harrington
October 25, 2012
Part 1: Oral Anticoagulants
Presentation TCT 2012

Part 1: Oral Anticoagulants

Presenter: Christopher Granger
October 25, 2012
Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?
Presentation TCT 2012

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presenter: Rajesh Dave
October 25, 2012
Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!
Presentation TCT 2012

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Gilles Montalescot
October 25, 2012
Debate: Clopidogrel is Enough and Still Plays a Role for Most!
Presentation TCT 2012

Debate: Clopidogrel is Enough and Still Plays a Role for Most!

Presenter: Michael Love
October 25, 2012
Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!
Presentation TCT 2012

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Roxana Mehran
October 25, 2012
ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes
Presentation TCT 2012

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presenter: Gregg Stone
October 25, 2012
Ticagrelor Update: PLATO: Recent Analyses
Presentation TCT 2012

Ticagrelor Update: PLATO: Recent Analyses

Presenter: Robert Harrington
October 24, 2012

Pagination

  • First page « First
  • Previous page ‹‹
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Current page 9
  • Page 10
  • Page 11
  • Page 12
  • Next page ››
  • Last page Last »
Advertisement
Become a Member

Register for TCTMD ®

Membership Plans
Sign Up for Our Newsletter

Receive the the latest news, research, and presentations from major meetings right to your inbox.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives. For more information, visit http://www.crf.org.

Main Navigation

  • News
  • Conferences
  • Slides
  • Videos
  • Podcasts
  • Fellows Forum
  • CV Team Forum
  • CME

Specialty Menu Navigation

  • COVID-19

  • Clinical

  • Coronary

  • Structural

  • Endovascular

  • Heart Failure

  • Heart Rhythm

  • Imaging & Physiology

  • Policy & Practice

Footer

  • Advertising & Sponsorships
  • About TCTMD ®
  • FAQs
  • Editorial Policy
  • Contact Us
  • About CRF ®
Digital Health Awards Winner - Spring 2017 eHealthcare Leadership Awards - 2018 Winner HON Code Certified
Copyright © 2025. TCTMD ® All rights reserved.
  • Privacy Policy
  • Terms of Use
Created by Constructive
Sign In

New at TCTMD? Register today!

Forgot Password

Forgot Your Password?

Enter the email you used to register to reset your password.

Search TCTMD
cme
CME TITLE
Sign up for our newsletter

Sign up to receive the most important cardiovascular news, research, and major meeting presentations.

Address
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Main navigation

  • News
    • Conference News
    • Features
    • Opinion
  • Conferences
  • Slides
  • Specialties
    • COVID-19
    • Clinical
    • Coronary
    • Structural
    • Endovascular
    • Heart Failure
    • Heart Rhythm
    • Imaging & Physiology
    • Policy & Practice
  • Podcasts
    • Heart Sounds
    • Rox Heart Radio
    • TCTMD Talking Points
    • Taking It To Heart
    • Heart Valve Matters
  • Videos
    • All Videos
    • Interviews
    • Topical Discussions
    • On Record
    • Live Cases
    • Partner Content
  • Fellows Forum
  • CV Team Forum

Top User Menu

  • CME
  • Register
  • Login

Search TCTMD

Submit an Event
< >

Become a PREMIUM MEMBER or LOG IN to view exclusive content

This content is available for meeting attendees and/or Platinum Members

REGISTER for free or LOG IN to view this content

Now Playing